While OS data remain immature, a favorable trend was observed in the surgery group (HR 0.67).
← all excerpts
Optimal treatment selection for hepatocellular carcinoma in the era of immunotherapy.
1
—
—
While OS data remain immature, a favorable trend was observed in the surgery group (HR 0.67).